Journal Mobile Options
Table of Contents
Vol. 33, No. 1, 2003
Issue release date: June 2003
Section title: Paper
Pathophysiol Haemost Thromb 2003;33:4–15

Calibrated Automated Thrombin Generation Measurement in Clotting Plasma

Hemker H.C.a · Giesen P.a · Al Dieri R.a · Regnault V.b · de Smedt E.a · Wagenvoord R.a · Lecompte T.b · Béguin S.a,b
aSynapse BV, Cardiovascular Research Institute, University of Maastricht, Maastricht, The Netherlands; bINSERM ERIT-M 0323 et EA 3452, Faculté de Médecine, Université Henri Poincaré, Nancy, France
email Corresponding Author

H.C. Hemker, MD, PhD

Synapse BV


NL–6200MD Maastricht (The Netherlands)

Tel. +31 43 3881 675, Fax +31 43 3884 570,


  1. Biggs R, Macfarlane RG: Human Blood Coagulation and its Disorders. Oxford, Blackwell, 1953.
  2. Macfarlane RG, Biggs R: A thrombin generation test. J Clin Pathol 1953;6:3–7.
  3. Pitney WR, Dacie J: A simple method of studying the generation of thrombin in recalcified plasma. J Clin Pathol 1953;6:9–13.
  4. Seegers WH: A personal perspective on hemostasis and thrombosis (1937–1981). Semin Thromb Hemost 1981;7:177–307.
  5. Hemker HC, Béguin S: Phenotyping the clotting system. Thromb Haemost 2000;84:747–751.
  6. Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Béguin S, Hemker HC: The thrombogram in rare inherited coagulation disorders: Its relation to clinical bleeding. Thromb Haemost 2002;88:576–582.
  7. Keularts IM, Hamulyak K, Hemker HC, Béguin S: The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost 2000;84:638–642.
  8. Keularts IMLW, Zivelin A, Seligsohn U, Hemker HC, Béguin S: The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001;85:1060–1065.
  9. Al Dieri L, Wagenvoord R, van Dedem GWK, Béguin S, Hemker HC: The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif – The C-domain. J Thromb Haemost 2003;1:907–914.
  10. Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, Gustafsson D: Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002;87:300–305.
  11. Kyrle PA, Mannhalter C, Béguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S: Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998;18:1287–1291.
  12. Wielders S, Mukherjee M, Michiels J, Rijkers DT, Cambus JP, Knebel RW, Kakkar V, Hemker HC, Béguin S: The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997;77:629–636.
  13. Duchemin J, Pittet JL, Tartary M, Béguin S, Gaussem P, Alhenc-Gelas M, Aiach M: A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost 1994;71:331–338.
  14. Rotteveel RC, Roozendaal KJ, Eijsman L, Hemker HC: The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 1993;70:959–962.
  15. Rosing J, Tans G, Nicolaes GA, Thomassen MC, Van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC: Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233–238.
  16. Regnault V, Béguin S, Wahl D, de Maistre E, Hemker HC, Lecompte T: Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003;89:208–212.
  17. Béguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC: Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999;93:564–570.
  18. Eagle H: Studies on blood coagulation. I. The role of prothrombin and of platelets in the formation of thrombin. J Gen Physiol 1934;18:531–545.
    External Resources
  19. Kessels H, Béguin S, Andree H, Hemker HC: Measurement of thrombin generation in whole blood – The effect of heparin and aspirin. Thromb Haemost 1994;72:78–83.
  20. Herault JP, Dol F, Gaich C, Bernat A, Herbert JM: Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost 1999;81:957–960.
  21. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS: Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and ‘clinical restenosis’. J Clin Invest 1996;98:863–874.
  22. Altman R, Scazziota A, Rouvier J, Gonzalez C: Effect of sodium arachidonate on thrombin generation through platelet activation – Inhibitory effect of aspirin. Thromb Haemost 2000;84:1109–1112.
  23. Ramjee MK: The use of fluorogenic substrates to monitor thrombin generation for the analysis of plasma and whole blood coagulation. Anal Biochem 2000;277:11–18.
  24. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Béguin S: The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000;83:589–591.
  25. Chantarangkul V, Clerici M, Bressi C, Tripodi A: Thrombin generation assessed as endogenous thrombin potential (ETP) in patients with hyper- or hypo-coagulability. Effects of phospholipids, tissue factor and residual platelets on the measurement performed in platelet-poor and platelet-rich plasma. Haematologica 2003;88:547–554.
  26. Regnault V, De Maistre E, Geschier C, Briquel ME, André E, Stoltz JF, Lecompte T: A new fast one-step immunopreparation for activated protein C. Thromb Haemost 1995;73:136.
  27. Barrett AJ: Alpha2-macroglobulin. Methods Enzymol 1981;80:737–754.
  28. Udenfriend S: Fluorescence Assay in Biology and Medicine. New York, Academic Press, 1996, vol 1, pp13, 118, vol 2, pp182–185.
  29. Hemker HC, Wielders S, Kessels H, Béguin S: Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617–624.
  30. Béguin S, Lindhout T, Hemker HC: The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost, 1989;61:25–29.
  31. Kumar R, Béguin S, Hemker HC: The influence of fibrinogen and fibrin on thrombin generation – Evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994;72:713–721.
  32. Bendayan P, Boccalon H, Dupouy D, Boneu B: Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994;71:576–580.
  33. Weitz JI, Hudoba M,Massel D,Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385–391.
  34. Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA: Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. J Lab Clin Med 1991;117:359–364.
  35. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP: Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993;91:1877–1883.
  36. Hemker HC: Thrombin generation, an essential step in haemostasis and thrombosis; in Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds): Haemostasis and Thrombosis. Edinburgh, Churchill Livingstone, 1994, pp 477–490.
  37. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311–2315.
  38. Butenas S, Branda RF, van’t Veer C, Cawthern KM, Mann KG: Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001;86:660–667.
  39. Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J: Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002;88:5–11.
  40. Mercier E, Quere I, Chabert R, Lallemant JG, Daures JP, Berlan J, Gris JP: The 20210A allele of the prothrombin gene is an independent risk factor for perception deafness in patients with venous thromboembolic antecedents. Blood 1999;93:3150–3152.
  41. Redondo M, Watzke HH, Stucki B, Sulzer I, Biasiutti FD, Binder BR, Furlan M, Lammle B, Wuillemin WA: Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease: High factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:1020–1025.
  42. Eldor A: Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001;86:104–111.
  43. Escuriola Ettingshausen C, Halimeh S, Kurnik K, Schobess R, Wermes C, Junker R, Kreuz W, Pollmann H, Nowak-Gottl U: Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001;85:218–220.
  44. Vianello F, Belvini D, Dal Bello F, Tagariello G, Zanon E, Lombardi AM, Zerbinati P, Girolami A: Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)→T) and heterozygous factor V Leiden. Haemophilia 2001;7:511–514.
  45. Tizzano EF, Soria JM, Coll I, Guzman B, Cornet M, Altisent C, Martorell M, Domenech M, del Rio E, Fontcuberta J, Baiget M: The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors. Haematologica 2002;87:279–285.
  46. Turecek PL, Váradi K, Keil B, Negrier C, Berntorp E, Astermark J, Bordet J-C, Morfini M, Linari S, Schwarz HP: Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003;33:16–22.
    External Resources
  47. Hartert H: Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klin Wochenschr 1948;26:577–583.
  48. Hartert H: Resonance-thrombography: Theoretical and practical elements. Biorheology 1981;18:693–701.
  49. Calatzis A, Fritzsche P, Kling M, Hipp R, Stemberger A: A comparison of the technical principle of the roTEG coagulation analyzer and conventional thrombelastographic systems (abstract). Ann Haematol 1996;72(suppl 1):P90.
  50. Laforce WR, Brudno DS, Kanto WP, Karp WB: Evaluation of the SonoClot Analyser for the measurement of platelet function in whole blood. Ann Clin Lab Sci 1992;22:30–33.
  51. Carr ME, Zekert SL: Measurement of platelet-mediated force development during plasma clot formation. Am J Med Sci 1991;302:13–18.
  52. Ramstrom S, Ranby M, Lindahl TL: The role of platelets in blood coagulation – Effects of platelet agonists and GPIIb/IIIa inhibitors studied by free oscillation rheometry. Thromb Res 2002;105:165–172.
  53. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J: Whole blood coagulation thrombelastic profiles employing minimal tissue factor activation. J Thromb Haemost 2003,1:551–558.
  54. De Cristofaro R, Landolfi R: Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: Applicability and limitations. Blood Coagul Fibrinolysis 1998;9:251–259.